Revance Therapeutics (RVNC) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Revance Therapeutic (RVNC) PT Raised to $32 at Goldman Sachs
February 20, 2020 6:09 AM ESTGoldman Sachs analyst Terence Flynn raised the price target on Revance Therapeutic (NASDAQ: RVNC) to $32.00 (from $25.00) while maintaining a Buy rating.... More
